Rheumatic heart disease is a systemic immune process that is sequelae to a beta-hemolytic streptococcal infection of the pharynx. It is most common in developing countries. However, it is responsible for 250,000 deaths in young people worldwide each year. Over 15 million people have evidence of rheumatic heart disease.
Rheumatic heart disease results from either single or repeated attacks of rheumatic fever that results in rigidity and deformity of valve cusps, the fusion of the commissures, or shortening and fusion of the chordae tendineae. Over 2 to 3 decades, valvular stenosis and/or regurgitation results. In chronic rheumatic heart disease, the mitral valve alone is the most commonly affected valve in an estimated 50 to 60% of cases. Combined lesions of both the aortic and mitral valves occur in 20% of cases. Involvement of the tricuspid valve occurs in about 10% of cases but only in association with mitral or aortic disease. Tricuspid valve cases are thought to be more common when recurrent infections have occurred. The pulmonary valve is rarely affected.
Rheumatic heart disease (RHD) is the most critical form of acquired heart disease in children and young adults living in developing countries. RHD accounts for approximately 15 to 20 percent of all patients with heart failure in endemic countries.
A study of rheumatic heart disease cases estimated that in 2015, there were globally 33.4 million cases of RHD, 10.5 million disability-adjusted life-years due to RHD, and 319400 deaths due to RHD. The incidence of rheumatic heart disease is highest in Oceania, central sub-Saharan Africa, and South Asia. In 2015, there was noted to be 3.4 cases per 100,000 population in nonendemic countries and 444 cases per 100,000 population in endemic countries.
Rheumatic heart disease affects predominantly those living in poverty with inadequate access to health care and unchecked exposure to group A streptococcus. A systematic review and meta-analysis calculated the prevalence of clinically silent RHD (21.1 per 1000 people) to be approximately seven to eight times higher than that of clinically manifest disease (2.7 per 1000 people). Prevalence of rheumatic heart disease increases with age, from 4.7 per 1000 children at 5 years of age to 21.0 per 1000 children at 16 years of age. Based on this data, estimates are that the RHD burden could increase by as much as double than that in the Global Burden of Disease study. Based on the fact that children in sub-Saharan Africa represent 6 to 7 percent of total global RHD burden, there may be an estimated 50 to 80 million persons currently affected with RHD worldwide.
Rheumatic heart disease is the result of valvular damage caused by an abnormal immune response to Streptococcus pyogenes infection, which is classified as a group A streptococcus that causes acute rheumatic fever.. Acute rheumatic fever occurs around three weeks after group A streptococcal pharyngitis that can affect joints, skin, brain, and heart. After multiple episodes of rheumatic fever, progressive fibrosis of heart valves can occur, which can lead to rheumatic valvular heart disease. If valvular heart disease remains untreated, then heart failure or death may occur. The precise pathophysiology is not well known. Rheumatic carditis is characterized by Aschoff nodules and MacCallum plaques. Aschoff bodies are seen in nodules the hearts affected with rheumatic fever. They result from inflammation in the heart muscleMacCallum plaques are seen on the valves and the subendocardium in the left atrium.
Rheumatic fever is the primary cause of acquired heart disease in children and young adults worldwide. Rheumatic fever occurs 2 to 3 weeks after a group A beta-hemolytic streptococcal pharyngeal infection.
Carditis is the most serious presentation of rheumatic fever. The symptoms and signs of carditis are dependent on the areas of the heart involved, which includes pericardium, myocardium or heart valves. The presentation of a pericardial friction rub on auscultation leans toward the diagnosis of pericarditis. The presence of signs of congestive heart failure points toward a diagnosis of myocarditis, which includes but not limited to lower extremity edema, shortness of breath with exertion or rest, abdominal distension, or inability to lay flat due to shortness of breath (orthopnea). Myocarditis in the absence of valvular disease is unlikely to be rheumatic in origin. Therefore, an apical systolic or basal diastolic murmur should be auscultated on physical exam. Mitral regurgitation is the most common valvular lesion, which is an apical pan-systolic murmur on auscultation. Aortic regurgitation is less common. If patients have a known history of rheumatic heart disease, a change in the character of the murmur or presence of a new murmur on auscultation leads to the diagnosis of acute rheumatic heart fever. Rheumatic heart disease predominantly affects the left-sided cardiac valves. The tricuspid valve and rarely pulmonary valve can be affected, but very unlikely without mitral valve involvement.
Rheumatic heart disease has a variety of clinical manifestations including myocarditis, decompensated congestive heart failure, arrhythmias (i.e., atrial fibrillation), and valvular heart disease.
Myocarditis can result in conduction disturbances in the heart. Therefore, an EKG is necessary. An EKG can show varying forms of heart block including first degree, second degree or third degree AV block.
A chest x-ray should be completed to evaluate for cardiomegaly or pulmonary vascular congestion, which can be signs of congestive heart failure.
A transthoracic echocardiogram is more sensitive and specific than auscultation during physical examination for detection of rheumatic heart disease. Rheumatic heart disease seen on transthoracic echo without evidence of a murmur on auscultation is “subclinical rheumatic heart disease.”
Mitral regurgitation is the most common presentation of rheumatic heart disease in young people. However, rheumatic heart disease is the most common cause of mitral stenosis worldwide. Common descriptions of the mitral valve on echocardiography are ‘dog-leg’ ‘elbow’ or ‘hockey-stick’ deformities, which all help describe the thickening and restricted motion of the anterior mitral valve leaflet.
In 2012, the World Heart Federation released criteria for echocardiographic diagnosis of rheumatic heart disease. The criteria are dependent on age and are broken down into older or younger than 20 years old.
Echocardiographic criteria for individuals aged less than or equal to 20 years old:
Definite Rheumatic Heart Disease (either A, B, C, or D):
A: Pathological mitral regurgitation and at least two morphological features of Rheumatic Heart Disease of the mitral valve
B: Mitral stenosis mean gradient greater than or equal to 4 mmHg
C: Pathological aortic regurgitation and at least two morphological features of rheumatic heart disease of the aortic valve
D: Borderline disease of both the aortic valve and mitral valve
Borderline Rheumatic Heart Disease (either A, B, or C):
A: At least two morphological features of rheumatic heart disease of the mitral valve without pathological mitral regurgitation or mitral stenosis
B: Pathological mitral regurgitation
C: Pathological aortic regurgitation
Normal echocardiographic findings (all four):
Echocardiographic criteria for individuals aged greater than 20 years old:
Definite Rheumatic Heart Disease (any one of the four):
Morphological Features of Rheumatic Heart Disease:
Pathologic mitral regurgitation (All four doppler criteria must be met):
Pathologic aortic regurgitation (All four Doppler criteria must be met):
Management of rheumatic heart disease can be broken down into prevention and long-term management. Primary prevention of rheumatic heart disease centers on speedy recognition of treatment of group A streptococcal pharyngitis to prevent the development of acute rheumatic fever. Intramuscular benzathine penicillin G is the most widely used antibiotic to treat group A streptococcal pharyngitis.
If a patient has a proven diagnosis of acute rheumatic fever, the goal of treatment is to suppress the inflammatory response to minimize the effects of inflammation on the heart and joints. According to the World Heart Federation, the only cost-effective approach to preventing progression of rheumatic heart disease is secondary prophylaxis in the form of penicillin injections every 3 to 4 weeks to prevent recurrent group A streptococcal infection that causes recurrent episodes of acute rheumatic fever, which leads to progression of rheumatic heart disease. The optimal duration of secondary prevention is unknown.
Percutaneous mitral balloon valvuloplasty is the standard first-line therapy for cases of rheumatic mitral stenosis in the absence of regurgitation, arrhythmias and left atrial thrombus. Surgical intervention is commonly the mainstay of treatment in severe cases of valvular disease. Surgical intervention can either be valve replacement or repair.
If a patient develops heart failure due to valve disease, the patient should be placed on medical therapy as tolerated for heart failure including ACE inhibitors, diuretics, and beta blockers.
At this time, there is no cure of rheumatic heart disease.
The physician should also have appropriate surveillance on patients diagnosed with rheumatic fever and rheumatic heart disease to allow for initiation of appropriate therapy as early as possible.
Rheumatic heart disease causes at least 200000 to 250000 premature deaths every year. It is also the major cause of cardiovascular death in children and young adults in countries that have poor medical attention. If the valvular disease is not serially monitored, the patient may not present until severe heart failure is present resulting in surgical contraindication.
Rheumatic heart disease is generally latent or silent until cardiac complications develop in late adulthood. Infective endocarditis, an embolic event, heart failure, pulmonary hypertension, and atrial fibrillation from untreated severe valvular disease are the most common complications.
Rheumatic heart disease is highly prevalent in developing countries leading to the cause of the most cardiovascular morbidity and mortality in young people. Guidelines provided by the World Health Federation have outlined that the most cost-effective way to prevent rheumatic heart disease is with antibiotic prophylaxis after the diagnosis of rheumatic fever. Patients should be informed of their diagnosis of rheumatic fever as well as the complications associated with poor compliance with antibiotics and follow-up including valvular heart disease, heart failure, and arrhythmias.
Primary care physicians and nurse practitioners who have patients with a known diagnosis of rheumatic fever should maintain and stress the importance of strict follow-up with the patients. To prevent rheumatic heart disease, patients should undergo close monitoring with complete history and physicals and transthoracic echocardiography. Patients should be referred to cardiology if they start developing a new murmur, signs, and symptoms of heart failure, arrhythmia, or evidence of valvular disease on transthoracic echocardiography. Surgery is often required when the mitral and/or aortic valve is severely damaged.
|||Seckeler MD,Hoke TR, The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. Clinical epidemiology. 2011 Feb 22; [PubMed PMID: 21386976]|
|||Bocchi EA,Guimarães G,Tarasoutshi F,Spina G,Mangini S,Bacal F, Cardiomyopathy, adult valve disease and heart failure in South America. Heart (British Cardiac Society). 2009 Mar; [PubMed PMID: 18977804]|
|||Watkins DA,Johnson CO,Colquhoun SM,Karthikeyan G,Beaton A,Bukhman G,Forouzanfar MH,Longenecker CT,Mayosi BM,Mensah GA,Nascimento BR,Ribeiro ALP,Sable CA,Steer AC,Naghavi M,Mokdad AH,Murray CJL,Vos T,Carapetis JR,Roth GA, Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015. The New England journal of medicine. 2017 Aug 24; [PubMed PMID: 28834488]|
|||Rothenbühler M,O'Sullivan CJ,Stortecky S,Stefanini GG,Spitzer E,Estill J,Shrestha NR,Keiser O,Jüni P,Pilgrim T, Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents. The Lancet. Global health. 2014 Dec; [PubMed PMID: 25433627]|
|||Weinberg J,Beaton A,Aliku T,Lwabi P,Sable C, Prevalence of rheumatic heart disease in African school-aged population: Extrapolation from echocardiography screening using the 2012 World Heart Federation Guidelines. International journal of cardiology. 2016 Jan 1; [PubMed PMID: 26402451]|
|||Marijon E,Mirabel M,Celermajer DS,Jouven X, Rheumatic heart disease. Lancet (London, England). 2012 Mar 10; [PubMed PMID: 22405798]|
|||Liu M,Lu L,Sun R,Zheng Y,Zhang P, Rheumatic Heart Disease: Causes, Symptoms, and Treatments. Cell biochemistry and biophysics. 2015 Jul; [PubMed PMID: 25638346]|
|||Reményi B,Wilson N,Steer A,Ferreira B,Kado J,Kumar K,Lawrenson J,Maguire G,Marijon E,Mirabel M,Mocumbi AO,Mota C,Paar J,Saxena A,Scheel J,Stirling J,Viali S,Balekundri VI,Wheaton G,Zühlke L,Carapetis J, World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline. Nature reviews. Cardiology. 2012 Feb 28; [PubMed PMID: 22371105]|
|||Nulu S,Bukhman G,Kwan GF, Rheumatic Heart Disease: The Unfinished Global Agenda. Cardiology clinics. 2017 Feb; [PubMed PMID: 27886787]|
|||Watkins DA,Beaton AZ,Carapetis JR,Karthikeyan G,Mayosi BM,Wyber R,Yacoub MH,Zühlke LJ, Rheumatic Heart Disease Worldwide: JACC Scientific Expert Panel. Journal of the American College of Cardiology. 2018 Sep 18; [PubMed PMID: 30213333]|